Acadia Pharmaceuticals (ACAD) Net Income Growth (3y) (2013 - 2026)
Acadia Pharmaceuticals (ACAD) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 47.10% |
| 10 | Acadia Pharmaceuticals | 4.35 Bn | 3.50 Bn | 243.27 Mn | 27.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.76% |
| Dec 31, 2025 | 46.00% |
| Sep 30, 2025 | 66.82% |
| Jun 30, 2025 | 40.67% |
| Mar 31, 2025 | 29.43% |
| Dec 31, 2024 | 77.94% |
| Sep 30, 2024 | 62.18% |
| Jun 30, 2024 | 40.29% |
| Mar 31, 2024 | 31.03% |
| Dec 31, 2023 | 39.02% |
| Sep 30, 2023 | 8.38% |
| Jun 30, 2023 | 26.54% |
| Mar 31, 2023 | 21.24% |
| Dec 31, 2022 | -146.07% |
| Sep 30, 2022 | 13.50% |
| Jun 30, 2022 | 14.77% |
| Mar 31, 2022 | -9.84% |
| Dec 31, 2021 | 9.65% |
| Sep 30, 2021 | 38.50% |
| Jun 30, 2021 | 11.49% |